Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 EV-to-EBITDA is 16.88 as of Jul. 14, 2026, which is 2% below its 10-year median of 17.17. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 57.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Boule Diagnostics AB's enterprise value is kr351.1 Mil.
Boule Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr20.8 Mil. Therefore, Boule Diagnostics AB's EV-to-EBITDA for today is 16.88.
The historical rank and industry rank for Boule Diagnostics AB's EV-to-EBITDA or its related term are showing as below:
CHIX:BOULs'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -180.91 Med: 17.17 Max: 168.6
Current: 16.88
During the past 13 years, the highest EV-to-EBITDA of Boule Diagnostics AB was 168.60. The lowest was -180.91. And the median was 17.17.
CHIX:BOULs's EV-to-EBITDA is ranked worse than 57.93% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs CHIX:BOULs: 16.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Boule Diagnostics AB (CHIX:BOULs) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boule Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Boule Diagnostics AB's share price for today is kr26.30.
Boule Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Boule Diagnostics AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's EV-to-EBITDA falls into.
Boule Diagnostics AB's current Enterprise Value is kr351.1 Mil.
Boule Diagnostics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a EV-to-EBITDA of 16.88 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Boule Diagnostics AB. This is near median its historical median of 17.17. According to the industry distribution chart, Boule Diagnostics AB ranks #296 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 57.9%.
Is Boule Diagnostics AB's EV-to-EBITDA too high?
Boule Diagnostics AB's current EV-to-EBITDA of 16.88 is near median its 10-year median of 17.17. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.20. Boule Diagnostics AB's value of 16.88 is 18.9% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #296 out of 511 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #296 out of 511 companies for EV-to-EBITDA. This places Boule Diagnostics AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. Boule Diagnostics AB's value of 16.88 is 18.9% above this benchmark. While the company's 10-year median is 17.17 vs. the industry median of 14.20, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current EV-to-EBITDA of 16.88 is 18.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Boule Diagnostics AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EV-to-EBITDA is 16.88, which is near median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current EV-to-EBITDA of 16.88. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current EV-to-EBITDA is 16.88, which is near median its 10-year median of 17.17 and 18.9% above the Medical Devices & Instruments industry median of 14.20. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current EV-to-EBITDA is 16.88 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.
Key valuation signals for CHIX:BOULS:
EV-to-EBITDA: 16.88 (near median its 10-year median of 17.17)
GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
Industry Position: 18.9% above the Medical Devices & Instruments median (#296 of 511)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
